A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.

Irene M GhobrialRavi VijDavid SiegelAshraf BadrosJonathan KaufmanNoopur RajeAndrzej JakubowiakMichael R SavonaMihaela ObrejaJesus G Berdeja

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

This study demonstrated promising efficacy of single-agent oprozomib in patients with relapsed multiple myeloma and Waldenström macroglobulinemia.

Keyphrases